Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
51
IVA Quote, Financials, Valuation and Earnings
Last price:
$4.64
Seasonality move
:
11.95%
Day range:
$4.60 - $4.72
52-week range:
$2.11 - $7.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
27.07x
P/B ratio:
12.49x
Volume:
227.7K
Avg. volume:
211.3K
1-year change:
117.29%
Market cap:
$678.2M
Revenue:
$9.9M
EPS (TTM):
-$2.22
Analysts' Opinion
-
Consensus RatingInventiva SA has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.33, Inventiva SA has an estimated upside of 229.75% from its current price of $4.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $4.65.
Fair Value
-
According to the consensus of 8 analysts, Inventiva SA has 229.75% upside to fair value with a price target of $15.33 per share.
IVA vs. S&P 500
-
Over the past 5 trading days, Inventiva SA has overperformed the S&P 500 by 7.47% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Inventiva SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Inventiva SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Inventiva SA reported revenues of --.
Earnings Growth
-
Inventiva SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Inventiva SA reported earnings per share of --.
Enterprise value:
626.9M
EV / Invested capital:
--
Price / LTM sales:
27.07x
EV / EBIT:
--
EV / Revenue:
42.42x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-6.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-171.62%
Net Income Margin (TTM):
-667.09%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $3.5M | $6.5M | $345K | $81.5K | $78.3K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$38.4M | -- | -- | -$9.8M | -$16.5M | |
| EBITDA | -$41.5M | -- | -- | -$9.4M | -$16.9M | |
| Diluted EPS | -$1.90 | -- | -- | -$0.25 | -$0.45 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $130.7M | $104.4M | $56.9M | $30.7M | -- | |
| Total Assets | $139.5M | $113.2M | $77M | $42.3M | -- | |
| Current Liabilities | $17.7M | $25.1M | $41.1M | $51.6M | -- | |
| Total Liabilities | $34.1M | $40.4M | $85.3M | $127M | -- | |
| Total Equity | $105.3M | $72.8M | -$8.3M | -$84.7M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$42.6M | -$18.7M | -$31.8M | -$3.9M | -$14.5M | |
| Cash From Investing | -$1.3M | -- | -- | -$1.1M | -$2M | |
| Cash From Financing | -$215.8K | -- | -- | $11M | $56.6K | |
| Free Cash Flow | -$43.1M | -- | -- | -- | -- | |
IVA
Sector
Market Cap
$678.2M
$28.1M
Price % of 52-Week High
58.25%
50%
Dividend Yield
0%
0%
Shareholder Yield
-23.15%
-1.54%
1-Year Price Total Return
117.29%
-17.67%
Beta (5-Year)
0.708
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.47
200-day SMA
Buy
Level
$4.06
Bollinger Bands (100)
Sell
Level
4.05 - 5.59
Chaikin Money Flow
Buy
Level
503.1K
20-day SMA
Buy
Level
$4.39
Relative Strength Index (RSI14)
Buy
Level
57.01
ADX Line
Buy
Level
16.17
Williams %R
Sell
Level
-11.6667
50-day SMA
Buy
Level
$4.43
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Sell
Level
-591.1K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.3809)
Sell
CA Score
(Annual)
Level (-10.9722)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (16.2668)
Sell
Piotroski F Score
(Annual)
Level (3)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Stock Forecast FAQ
In the current month, IVA has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IVA average analyst price target in the past 3 months is $15.33.
-
Where Will Inventiva SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Inventiva SA share price will rise to $15.33 per share over the next 12 months.
-
What Do Analysts Say About Inventiva SA?
Analysts are divided on their view about Inventiva SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Inventiva SA is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Inventiva SA's Price Target?
The price target for Inventiva SA over the next 1-year time period is forecast to be $15.33 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Inventiva SA is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IVA?
You can purchase shares of Inventiva SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Inventiva SA shares.
-
What Is The Inventiva SA Share Price Today?
Inventiva SA was last trading at $4.64 per share. This represents the most recent stock quote for Inventiva SA. Yesterday, Inventiva SA closed at $4.65 per share.
-
How To Buy Inventiva SA Stock Online?
In order to purchase Inventiva SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get IVA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IVA
Sector
P/E ratio
--
23.88x
PEG ratio
-0.01x
-0.01x
P/B ratio
12.49x
1.82x
Price / LTM sales
27.07x
1.59x
Growth Metrics
IVA
Sector
Revenue growth
--
4.73%
Earnings growth
--
11.11%
Revenue (5-year growth)
4.9%
6.46%
Earnings forecast
-$0.18
-$0.18
Profitability
IVA
Sector
Profitability FY 2024
$6.1M
$3.6M
Return on invested capital
--
-31.77%
Return on assets
-171.62%
-28.18%
Return on equity
--
-37.47%
Earnings Date
Last Earnings Date
Sep
29
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Dec
29
Balance Sheet
IVA
Sector
Total cash
$10.9M
$26.3M
Short term investments
--
$26M
Total assets
$122.8M
$76.9M
Long term debt
$50.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 6.12% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.13% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 7.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
